This finding, together with the increased sensitivity to oxidative channel inhibition caused by MYBBP1A downregulation in vitro, suggests a possible alternative therapy for a subgroup of renal carcinoma patients. This evidence concerns the gene MYBBP1A and renal carcinoma.